PHV-wordings
Ulipristalacetate
PSUR-outcome
|
24/02/2022
Further information can be found in the Commission Decision and its annexes, which are available in all EU languages on the European Commission's (EC) website.
Azithromycin
PSUR-outcome
|
22/02/2022
Further information and amendments to the product information in all EU languages are available on the EMA website.
Pregabalin
PRAC signal recommendation
|
22/02/2022
Risk for Toxic epidermal necrolysis. Further information and the changes to the product information in all EU languages are available on the EMA website.
Nadroparin
PSUR-outcome
|
17/02/2022
Further information and amendments to the product information in all EU languages are available on the EMA website.
Hydrochlorothiazide/Quinapril
PSUR-outcome
|
11/02/2022
Further information and amendments to the product information in all EU languages are available on the EMA website.
Quinapril
PSUR-outcome
|
11/02/2022
Further information and amendments to the product information in all EU languages are available on the EMA website.
Efavirenz
Additional template
|
11/02/2022
Further information is available in the CMDh press release (Report from the meeting held on 14-16 December 2021) on the HMA-Website.
Latanoprost
Additional template
|
11/02/2022
Further information is available in the CMDh press release (Report from the meeting held on 14-16 December 2021) on the HMA-Website.
Fentanyl (transmucosal)
Additional template
|
11/02/2022
Further information is available in the CMDh press release (Report from the meeting held on 14-16 December 2021) on the HMA-Website.
Chlororquine
Additional template
|
08/02/2022
Further information is available in the CMDh press release (Report from the meeting held on 14-16 December 2021) on the HMA-Website.
